Selandia Baru - Inggris - Medsafe (Medicines Safety Authority)

teva pharma (new zealand) limited - glatiramer acetate 20 mg/ml;   - solution for injection - 20 mg/ml - active: glatiramer acetate 20 mg/ml   excipient: mannitol water for injection - reduction of the frequency of relapses in patients with relapsing remitting multiple sclerosis. treatment of patients with a single clinical event suggestive of multiple sclerosis and at least two clinically silent mri lesions characteristic of multiple sclerosis, if alternative diagnoses have been excluded.

Israel - Inggris - Ministry of Health

merck serono ltd - interferon beta 1a - solution for injection - interferon beta 1a 44 mcg/ml - interferon beta-1a - interferon beta-1a - rebif (interferone beta-1a) is indicated for the treatment of patients with relapsing forms of multiple sclerosis to decrease the frequency of clinical exacerbations and delay the accumulation of physical disability. efficacy of rebif in chronic progressive multiple sclerosis has not been established.

Israel - Inggris - Ministry of Health

bayer israel ltd - interferon beta 1b - powder and solvent for solution for injection - interferon beta 1b 0.3 mg/vial - interferon beta-1b - interferon beta-1b - use in ambulatory patients with relapsing-remitting multiple sclerosis (rrms) and relapsing progressive m.s. to reduce the frequency of clinical exacerbations. treatment of secondary progressive (sp) form of multiple sclerosis. treatment of patients who have experienced a single demyelinating event with an active inflammatory process, if it is severe enough to warrant treatment with intravenous corticosteroids, if alternative diagnoses have been excluded, including the prescence of mri abnormalities characteristic of m.s. and if they are determined to be at high risk of developing clinically definite multiple sclerosis.

Israel - Inggris - Ministry of Health

sanofi israel ltd - hydroxychloroquine sulfate - film coated tablets - hydroxychloroquine sulfate 200 mg - hydroxychloroquine - hydroxychloroquine - plaquenil is indicated for the suppressive treatment and treatment of acute attacks of malaria due to plasmodium vivax, p. malaria. p. ovale and susceptible strains of p. falciparum it is also indicated for the treatment of discoid and sustemic lupus erythematosus and rheumatoid arthritis.

Irlandia - Inggris - HPRA (Health Products Regulatory Authority)

teva pharmaceuticals limited - glatiramer acetate - solution for injection - 20 mg/ml - other immunostimulants

Singapura - Inggris - HSA (Health Sciences Authority)

bayer (south east asia) pte ltd - interferon beta-1b - injection, powder, for solution - 0.25 mg/ml

Malta - Inggris - Medicines Authority

teva pharmaceuticals limited ridings point, whistler drive, castleford, west yorkshire wf10 5hx, united kingdom - glatiramer acetate - solution for injection - glatiramer acetate 20 mg/ml - immunostimulants

Irlandia - Inggris - HPRA (Health Products Regulatory Authority)

generics (uk) limited - glatiramer acetate - solution for injection in pre-filled syringe - 20 milligram(s)/millilitre - other immunostimulants; glatiramer acetate

Uni Eropa - Inggris - EMA (European Medicines Agency)

bayer ag  - interferon beta-1b - multiple sclerosis - immunostimulants, - betaferon is indicated for the treatment ofpatients with a single demyelinating event with an active inflammatory process, if it is severe enough to warrant treatment with intravenous corticosteroids, if alternative diagnoses have been excluded, and if they are determined to be at high risk of developing clinically definite multiple sclerosis;patients with relapsing-remitting multiple sclerosis and two or more relapses within the last two years;patients with secondary progressive multiple sclerosis with active disease, evidenced by relapses.

Uni Eropa - Inggris - EMA (European Medicines Agency)

novartis europharm limited - interferon beta-1b - multiple sclerosis - immunostimulants, - extavia is indicated for the treatment of:patients with a single demyelinating event with an active inflammatory process, if it is severe enough to warrant treatment with intravenous corticosteroids, if alternative diagnoses have been excluded, and if they are determined to be at high risk of developing clinically definite multiple sclerosis;patients with relapsing-remitting multiple sclerosis and two or more relapses within the last two years;patients with secondary progressive multiple sclerosis with active disease, evidenced by relapses.